Bryan Smith, Ph.D. is an Associate Director and leads target discovery at Link Cell Therapies. He has over 10 years of experience in discovery oncology with a focus on identifying target antigens for immune-based therapeutics. Bryan previously worked at Arsenal Bio, where he drove efforts to define and characterize solid tumor target pairs for logic-gated cell therapies. Prior to Arsenal Bio, Bryan supported the development of allogeneic CAR T cells against novel solid tumor targets at Allogene Therapeutics.
Bryan obtained his B.A. in Biochemistry from DePauw University. He holds a Ph.D. from the University of Notre Dame, where he conducted research on in vivo detection of cell death using synthetic coordination complexes. He then pursued post-doctoral training with Owen Witte at UCLA on establishing new therapeutic targets for advanced epithelial cancers.
Bryan has co-authored 23 scientific publications and has received several awards and fellowships including a Prostate Cancer Foundation Young Investigator Award and American Cancer Society Postdoctoral Fellowship.
